Form 4: Korro Bio Director Jean-Francois Formela Receives Significant Stock Option Grant

Korro Bio, Inc. Director Jean-Francois Formela was granted 6,010 stock options with an exercise price of $14.87, vesting on the earlier of one year or the next annual meeting, aligning his interests with long-term shareholder value.

Summary

• Jean-Francois Formela, a Director of Korro Bio, Inc. (KRRO), was granted 6,010 stock options on June 11, 2025.
• Each option represents the right to buy one share of Korro Bio Common Stock at an exercise price of $14.87.
• The options are set to vest in full on the earlier of the one-year anniversary of the grant date or the date of the next annual meeting of stockholders.
• Vesting is contingent upon Mr. Formela's continued service as a non-employee director through the applicable vesting date.
• The granted stock options have an expiration date of June 10, 2035.
• Following this transaction, Mr. Formela beneficially owns 6,010 derivative securities, specifically these stock options.

Sentiment

Score: 7

Explanation: The document reports a routine grant of stock options to a director, which is a standard practice for aligning interests and incentivizing long-term commitment. It does not contain any negative operational or financial news, indicating a neutral to slightly positive sentiment due to incentive alignment.

Positives

• The grant of stock options aligns the director's financial interests directly with those of the shareholders, incentivizing long-term company performance and value creation.
• The vesting schedule encourages the continued service and commitment of a non-employee director, ensuring stability and experience on the board.

Future Outlook

The stock options are designed to vest over time, contingent on the director's continued service, indicating an expectation of ongoing contribution to the company's strategic direction and performance.

Industry Context

The granting of stock options to non-employee directors is a common and standard practice across publicly traded companies, particularly within the biotechnology and pharmaceutical sectors, serving as a key component of director compensation to align their incentives with long-term shareholder value creation.

Comparison to Industry Standards

• The practice of granting stock options to non-employee directors is a standard compensation mechanism across publicly traded companies, including those in the biotech sector like Moderna (MRNA) or BioNTech (BNTX), to attract and retain qualified board members and align their interests with company performance.
• The vesting schedule, typically over one year or until the next annual meeting, is also a common structure for such grants, similar to practices observed at companies like Vertex Pharmaceuticals (VRTX) or Regeneron Pharmaceuticals (REGN) for their non-executive directors.

Corporate Governance

Related Party Transactions

• Grant of 6,010 stock options to Jean-Francois Formela, a Director of Korro Bio, Inc., with an exercise price of $14.87, representing a transaction with a related party.

Stakeholder Impact

• Shareholders: The grant aims to align the director's interests with shareholders, potentially fostering better long-term performance, though it also represents potential future dilution if options are exercised.
• Employees: No direct impact on employees is mentioned in this filing.

Next Steps

• Continued service of Jean-Francois Formela as a non-employee director for the options to vest according to the specified schedule.
• Potential exercise of the stock options by Jean-Francois Formela after they have vested.

Key Dates

Keywords

Korro Bio, KRRO, Form 4, Stock Option, Director Compensation, Insider Transaction, Beneficial Ownership, Equity Compensation